1-7 of 7
Chetan Lathia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Free
Carol Peña, Chetan Lathia, Minghua Shan, Bernard Escudier, Ronald M. Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19): 4853–4863.
https://doi.org/10.1158/1078-0432.CCR-09-3343
Published: 29 September 2010
View articletitled, Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Open the PDF for Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial in another window
Journal Articles

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

Free
Keith T. Flaherty, Joan Schiller, Lynn M. Schuchter, Glenn Liu, David A. Tuveson, Maryann Redlinger, Chetan Lathia, Chenghua Xia, Oana Petrenciuc, Sunil R. Hingorani, Michael A. Jacobetz, Patricia A. Van Belle, David Elder, Marcia S. Brose, Barbara L. Weber, Mark R. Albertini, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15): 4836–4842.
https://doi.org/10.1158/1078-0432.CCR-07-4123
Published: 01 August 2008
View articletitled, A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
Open the PDF for A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel in another window
Journal Articles

Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors

Free
Ignacio Duran, Sebastien J. Hotté, Holger Hirte, Eric X. Chen, Martha MacLean, Sandra Turner, Lixia Duan, Gregory R. Pond, Chetan Lathia, Scott Walsh, John J. Wright, Janet Dancey, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (16): 4849–4857.
https://doi.org/10.1158/1078-0432.CCR-07-0382
Published: 15 August 2007
View articletitled, Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors
Open the PDF for Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Free
Kim Margolin, Michael B. Atkins, Janice P. Dutcher, Marc S. Ernstoff, John W. Smith, II, Joseph I. Clark, Joseph Baar, Jeffrey Sosman, Jeffrey Weber, Chetan Lathia, Janice Brunetti, Frank Cihon, Brian Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3312–3319.
https://doi.org/10.1158/1078-0432.CCR-06-1341
Published: 01 June 2007
View articletitled, Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer
Open the PDF for Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer in another window
Journal Articles

Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer

Free
Alex A. Adjei, Julian R. Molina, Sumithra J. Mandrekar, Randolph Marks, Joel R. Reid, Gary Croghan, Lorelei J. Hanson, James R. Jett, Chenghua Xia, Chetan Lathia, Ronit Simantov
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (9): 2684–2691.
https://doi.org/10.1158/1078-0432.CCR-06-2889
Published: 01 May 2007
View articletitled, Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer
Open the PDF for Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer in another window
Journal Articles

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

Free
Lillian L. Siu, Ahmad Awada, Chris H. Takimoto, Martine Piccart, Brian Schwartz, Tom Giannaris, Chetan Lathia, Oana Petrenciuc, Malcolm J. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 144–151.
https://doi.org/10.1158/1078-0432.CCR-05-1571
Published: 05 January 2006
View articletitled, Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer
Open the PDF for Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer in another window
Journal Articles

Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors

Free
Jeffrey W. Clark, Joseph P. Eder, David Ryan, Chetan Lathia, Heinz-Josef Lenz
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5472–5480.
https://doi.org/10.1158/1078-0432.CCR-04-2658
Published: 01 August 2005
View articletitled, Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors
Open the PDF for Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors in another window